<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537274</url>
  </required_header>
  <id_info>
    <org_study_id>C97010</org_study_id>
    <secondary_id>MK-4031-016</secondary_id>
    <secondary_id>C97010</secondary_id>
    <nct_id>NCT03537274</nct_id>
  </id_info>
  <brief_title>Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)</brief_title>
  <official_title>Comparison of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) vs. Interferon Alfa-2B for Treatment of Adult Subjects With Chronic Hepatitis C Not Previously Treated With Interferon: Dose Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the efficacy of PEG-Intron (SCH 54031) in participants with chronic
      Hepatitis C virus (HCV) infection who have not been previously treated with interferon.
      Participants are randomized to receive one of three doses of PEG-Intron (0.5, 1.0, and 1.5
      mg/kg) or Interferon Alfa-2B for 48 weeks. The primary objective of this study is to evaluate
      the efficacy of PEG-Intron (compared to Interferon Alfa-2B) with respect to response based on
      loss of detectable HCV ribonucleic acid (HCV-RNA) and normalization of alanine transaminase
      (ALT) level after 24 weeks of therapy and at 24 weeks of follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 1997</start_date>
  <completion_date type="Actual">July 23, 1999</completion_date>
  <primary_completion_date type="Actual">July 23, 1999</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving Responder Status at 24 Weeks of Treatment</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The number of participants achieving responder status at 24 weeks of treatment was assessed. A participant was classified as a responder if, at 24 weeks of treatment, they met both of the following criteria: 1) HCV-Ribonucleic Acid (RNA) negative (defined as &lt;100 copies/mL serum by quantitative polymerase chain reaction [qPCR] assay); and 2) alanine transaminase (ALT) level normal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving Sustained Responder Status at 24 Weeks of Follow-up</measure>
    <time_frame>Up to 72 weeks (up to 48 weeks treatment and 24 weeks follow-up)</time_frame>
    <description>The number of participants achieving sustained responder status at 24 weeks of follow-up was assessed. A participant was classified as a sustained responder if, at 24 weeks of follow-up, they met both of the following criteria: 1) HCV-RNA negative (defined as &lt;100 copies/mL serum by qPCR assay); and 2) ALT level normal.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1224</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>PEG-Intron, 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-Intron, 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-Intron, 1.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon Alfa-2b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-Intron</intervention_name>
    <description>PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.</description>
    <arm_group_label>PEG-Intron, 0.5 mg/kg</arm_group_label>
    <arm_group_label>PEG-Intron, 1.0 mg/kg</arm_group_label>
    <arm_group_label>PEG-Intron, 1.5 mg/kg</arm_group_label>
    <other_name>SCH 54031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interferon Alfa-2B</intervention_name>
    <description>Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.</description>
    <arm_group_label>Interferon Alfa-2b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be serum positive for hepatitis C virus.

          -  Have liver biopsy within 1 year prior to entry, with a pathology report confirming a
             histological diagnosis consistent with chronic hepatitis.

          -  Have one abnormal historic ALT at least 6 months prior to screening, with elevated ALT
             at entry.

          -  Have compensated liver disease, testing negative for HIV and serum hepatitis B surface
             antigen (HBsAg) at entry.

          -  If male or female of childbearing potential, be practicing adequate contraception
             during treatment.

        Exclusion Criteria:

          -  Be female who is currently pregnant or nursing.

          -  Have prior treatment with any interferon.

          -  Have suspected hypersensitivity to alpha interferon.

          -  Have participated in any other clinical trial within 30 days of entry

          -  Have received treatment with any investigational drug within 30 days of entry.

          -  Have received prior treatment for hepatitis with any other antiviral or
             immunomodulatory drug within the previous 2 years.

          -  Have any other cause for the liver disease other than chronic hepatitis C including
             but not limited to: co-infection with hepatitis B virus; Hemochromatosis; alpha-1
             antitrypsin deficiency; Wilson's disease; autoimmune hepatitis; alcoholic liver
             disease; obesity-induced liver disease; and drug-related liver disease.

          -  Have hemophilia or any other condition that would prevent the participant from having
             a liver biopsy, including anticoagulant therapy.

          -  Have hemoglobinopathies (e.g., Thalassemia)

          -  Have evidence of advanced liver disease such as history or presence of ascites,
             bleeding varices, spontaneous encephalopathy.

          -  Have received organ transplants.

          -  Have a preexisting psychiatric condition, especially severe depression, or a history
             of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or
             attempt.

          -  Have central nervous system trauma or active seizure disorders requiring medication.

          -  Have significant cardiovascular dysfunction within the past 6 months (e.g., angina,
             congestive heart failure, recent myocardial infarction, severe hypertension or
             significant arrhythmia).

          -  Have poorly controlled diabetes mellitus.

          -  Have chronic pulmonary disease (e.g., chronic obstructive pulmonary disease).

          -  Have immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's
             disease, ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenia
             purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma,
             severe psoriasis, clinical cryoglobulinemia with vasculitis).

          -  Have any medical condition requiring, or likely to require during the course of the
             study, chronic systemic administration of steroids.

          -  Have history of substance abuse, such as alcohol, intravenous drugs and inhaled drugs.

          -  Have clinically significant retinal abnormalities.

          -  Be unable to abstain from the consumption of alcohol.

          -  Have any other condition which in the opinion of the investigator would make the
             patient unsuitable for enrollment, or could interfere with the patient participating
             in and completing the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <results_first_submitted>January 10, 2019</results_first_submitted>
  <results_first_submitted_qc>January 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2019</results_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In total, 1224 participants with chronic Hepatitis C virus (HCV) infection were randomized, with 1219 receiving study treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PEG-Intron, 0.5 mg/kg</title>
          <description>PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.</description>
        </group>
        <group group_id="P2">
          <title>PEG-Intron, 1.0 mg/kg</title>
          <description>PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.</description>
        </group>
        <group group_id="P3">
          <title>PEG-Intron, 1.5 mg/kg</title>
          <description>PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.</description>
        </group>
        <group group_id="P4">
          <title>Interferon Alfa-2b</title>
          <description>Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="298"/>
                <participants group_id="P3" count="304"/>
                <participants group_id="P4" count="307"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="297"/>
                <participants group_id="P3" count="304"/>
                <participants group_id="P4" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="229"/>
                <participants group_id="P3" count="228"/>
                <participants group_id="P4" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="76"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>PEG-Intron, 0.5 mg/kg</title>
          <description>PEG-Intron administered QW for 48 weeks at 0.5 mg/kg by SC injection.</description>
        </group>
        <group group_id="B2">
          <title>PEG-Intron, 1.0 mg/kg</title>
          <description>PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.</description>
        </group>
        <group group_id="B3">
          <title>PEG-Intron, 1.5 mg/kg</title>
          <description>PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.</description>
        </group>
        <group group_id="B4">
          <title>Interferon Alfa-2b</title>
          <description>Interferon Alfa-2b administered TIW for 48 weeks at 3 MIU by SC injection.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="315"/>
            <count group_id="B2" value="297"/>
            <count group_id="B3" value="304"/>
            <count group_id="B4" value="303"/>
            <count group_id="B5" value="1219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="9.4"/>
                    <measurement group_id="B2" value="43.7" spread="9.5"/>
                    <measurement group_id="B3" value="42.9" spread="8.7"/>
                    <measurement group_id="B4" value="42.6" spread="9.2"/>
                    <measurement group_id="B5" value="43.1" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="449"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="207"/>
                    <measurement group_id="B5" value="770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Responder Status at 24 Weeks of Treatment</title>
        <description>The number of participants achieving responder status at 24 weeks of treatment was assessed. A participant was classified as a responder if, at 24 weeks of treatment, they met both of the following criteria: 1) HCV-Ribonucleic Acid (RNA) negative (defined as &lt;100 copies/mL serum by quantitative polymerase chain reaction [qPCR] assay); and 2) alanine transaminase (ALT) level normal.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron, 0.5 mg/kg</title>
            <description>PEG-Intron administered QW for 48 weeks at 0.5 mg/kg by SC injection.</description>
          </group>
          <group group_id="O2">
            <title>PEG-Intron, 1.0 mg/kg</title>
            <description>PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>PEG-Intron, 1.5 mg/kg</title>
            <description>PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.</description>
          </group>
          <group group_id="O4">
            <title>Interferon Alfa-2b</title>
            <description>Interferon Alfa-2b administered TIW for 48 weeks at 3 MIU by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Responder Status at 24 Weeks of Treatment</title>
          <description>The number of participants achieving responder status at 24 weeks of treatment was assessed. A participant was classified as a responder if, at 24 weeks of treatment, they met both of the following criteria: 1) HCV-Ribonucleic Acid (RNA) negative (defined as &lt;100 copies/mL serum by quantitative polymerase chain reaction [qPCR] assay); and 2) alanine transaminase (ALT) level normal.</description>
          <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="297"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.078</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Sustained Responder Status at 24 Weeks of Follow-up</title>
        <description>The number of participants achieving sustained responder status at 24 weeks of follow-up was assessed. A participant was classified as a sustained responder if, at 24 weeks of follow-up, they met both of the following criteria: 1) HCV-RNA negative (defined as &lt;100 copies/mL serum by qPCR assay); and 2) ALT level normal.</description>
        <time_frame>Up to 72 weeks (up to 48 weeks treatment and 24 weeks follow-up)</time_frame>
        <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron, 0.5 mg/kg</title>
            <description>PEG-Intron administered QW for 48 weeks at 0.5 mg/kg by SC injection.</description>
          </group>
          <group group_id="O2">
            <title>PEG-Intron, 1.0 mg/kg</title>
            <description>PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>PEG-Intron, 1.5 mg/kg</title>
            <description>PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.</description>
          </group>
          <group group_id="O4">
            <title>Interferon Alfa-2b</title>
            <description>Interferon Alfa-2b administered TIW for 48 weeks at 3 MIU by SC injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Sustained Responder Status at 24 Weeks of Follow-up</title>
          <description>The number of participants achieving sustained responder status at 24 weeks of follow-up was assessed. A participant was classified as a sustained responder if, at 24 weeks of follow-up, they met both of the following criteria: 1) HCV-RNA negative (defined as &lt;100 copies/mL serum by qPCR assay); and 2) ALT level normal.</description>
          <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="297"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 72 weeks (up to 48 weeks treatment and 24 weeks of follow-up)</time_frame>
      <desc>Analysis population includes all randomized participants receiving ≥1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>PEG-Intron, 0.5 mg/kg</title>
          <description>PEG-Intron administered QW for 48 weeks at 0.5 mg/kg SC injection.</description>
        </group>
        <group group_id="E2">
          <title>PEG-Intron, 1.0 mg/kg</title>
          <description>PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.</description>
        </group>
        <group group_id="E3">
          <title>PEG-Intron, 1.5 mg/kg</title>
          <description>PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.</description>
        </group>
        <group group_id="E4">
          <title>Interferon Alfa-2b</title>
          <description>Interferon Alfa-2b administered TIW for 48 weeks at 3 MIU by SC injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ophthalmic vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Retinal exudates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Douglas' abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Body fat disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Nervous system neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Dependence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Uterine disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="291" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="296" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="293" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="13" subjects_at_risk="315"/>
                <counts group_id="E2" events="37" subjects_affected="18" subjects_at_risk="297"/>
                <counts group_id="E3" events="36" subjects_affected="25" subjects_at_risk="304"/>
                <counts group_id="E4" events="15" subjects_affected="7" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="315"/>
                <counts group_id="E2" events="37" subjects_affected="19" subjects_at_risk="297"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="315"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="297"/>
                <counts group_id="E3" events="19" subjects_affected="15" subjects_at_risk="304"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="315"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="304"/>
                <counts group_id="E4" events="18" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="28" subjects_at_risk="315"/>
                <counts group_id="E2" events="31" subjects_affected="24" subjects_at_risk="297"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="304"/>
                <counts group_id="E4" events="16" subjects_affected="14" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="75" subjects_affected="48" subjects_at_risk="315"/>
                <counts group_id="E2" events="51" subjects_affected="38" subjects_at_risk="297"/>
                <counts group_id="E3" events="54" subjects_affected="37" subjects_at_risk="304"/>
                <counts group_id="E4" events="39" subjects_affected="33" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="75" subjects_affected="53" subjects_at_risk="315"/>
                <counts group_id="E2" events="90" subjects_affected="58" subjects_at_risk="297"/>
                <counts group_id="E3" events="103" subjects_affected="69" subjects_at_risk="304"/>
                <counts group_id="E4" events="70" subjects_affected="50" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="315"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E3" events="28" subjects_affected="25" subjects_at_risk="304"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="315"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="297"/>
                <counts group_id="E3" events="20" subjects_affected="12" subjects_at_risk="304"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="114" subjects_affected="73" subjects_at_risk="315"/>
                <counts group_id="E2" events="128" subjects_affected="83" subjects_at_risk="297"/>
                <counts group_id="E3" events="130" subjects_affected="83" subjects_at_risk="304"/>
                <counts group_id="E4" events="95" subjects_affected="64" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E2" events="36" subjects_affected="23" subjects_at_risk="297"/>
                <counts group_id="E3" events="33" subjects_affected="23" subjects_at_risk="304"/>
                <counts group_id="E4" events="22" subjects_affected="20" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="89" subjects_affected="42" subjects_at_risk="315"/>
                <counts group_id="E2" events="89" subjects_affected="40" subjects_at_risk="297"/>
                <counts group_id="E3" events="120" subjects_affected="50" subjects_at_risk="304"/>
                <counts group_id="E4" events="63" subjects_affected="41" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="315"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="140" subjects_affected="106" subjects_at_risk="315"/>
                <counts group_id="E2" events="162" subjects_affected="120" subjects_at_risk="297"/>
                <counts group_id="E3" events="184" subjects_affected="133" subjects_at_risk="304"/>
                <counts group_id="E4" events="125" subjects_affected="99" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="279" subjects_affected="160" subjects_at_risk="315"/>
                <counts group_id="E2" events="283" subjects_affected="164" subjects_at_risk="297"/>
                <counts group_id="E3" events="287" subjects_affected="159" subjects_at_risk="304"/>
                <counts group_id="E4" events="295" subjects_affected="170" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="74" subjects_affected="57" subjects_at_risk="315"/>
                <counts group_id="E2" events="95" subjects_affected="66" subjects_at_risk="297"/>
                <counts group_id="E3" events="113" subjects_affected="76" subjects_at_risk="304"/>
                <counts group_id="E4" events="78" subjects_affected="59" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="189" subjects_affected="135" subjects_at_risk="315"/>
                <counts group_id="E2" events="166" subjects_affected="120" subjects_at_risk="297"/>
                <counts group_id="E3" events="164" subjects_affected="122" subjects_at_risk="304"/>
                <counts group_id="E4" events="49" subjects_affected="47" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="41" subjects_affected="20" subjects_at_risk="315"/>
                <counts group_id="E2" events="43" subjects_affected="27" subjects_at_risk="297"/>
                <counts group_id="E3" events="86" subjects_affected="24" subjects_at_risk="304"/>
                <counts group_id="E4" events="28" subjects_affected="21" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="89" subjects_affected="55" subjects_at_risk="315"/>
                <counts group_id="E2" events="87" subjects_affected="61" subjects_at_risk="297"/>
                <counts group_id="E3" events="90" subjects_affected="60" subjects_at_risk="304"/>
                <counts group_id="E4" events="64" subjects_affected="50" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="141" subjects_affected="96" subjects_at_risk="315"/>
                <counts group_id="E2" events="191" subjects_affected="124" subjects_at_risk="297"/>
                <counts group_id="E3" events="206" subjects_affected="127" subjects_at_risk="304"/>
                <counts group_id="E4" events="106" subjects_affected="86" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="315"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="304"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Liver tenderness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="315"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="297"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="304"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="315"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="297"/>
                <counts group_id="E3" events="19" subjects_affected="13" subjects_at_risk="304"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="315"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="297"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="304"/>
                <counts group_id="E4" events="29" subjects_affected="22" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="45" subjects_affected="36" subjects_at_risk="315"/>
                <counts group_id="E2" events="31" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E3" events="33" subjects_affected="27" subjects_at_risk="304"/>
                <counts group_id="E4" events="30" subjects_affected="24" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="315"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E3" events="37" subjects_affected="27" subjects_at_risk="304"/>
                <counts group_id="E4" events="29" subjects_affected="19" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="315"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="304"/>
                <counts group_id="E4" events="22" subjects_affected="14" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="45" subjects_affected="34" subjects_at_risk="315"/>
                <counts group_id="E2" events="45" subjects_affected="36" subjects_at_risk="297"/>
                <counts group_id="E3" events="91" subjects_affected="74" subjects_at_risk="304"/>
                <counts group_id="E4" events="46" subjects_affected="42" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="315"/>
                <counts group_id="E2" events="72" subjects_affected="59" subjects_at_risk="297"/>
                <counts group_id="E3" events="86" subjects_affected="76" subjects_at_risk="304"/>
                <counts group_id="E4" events="60" subjects_affected="49" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="145" subjects_affected="78" subjects_at_risk="315"/>
                <counts group_id="E2" events="116" subjects_affected="71" subjects_at_risk="297"/>
                <counts group_id="E3" events="159" subjects_affected="86" subjects_at_risk="304"/>
                <counts group_id="E4" events="124" subjects_affected="73" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="58" subjects_affected="46" subjects_at_risk="315"/>
                <counts group_id="E2" events="81" subjects_affected="57" subjects_at_risk="297"/>
                <counts group_id="E3" events="78" subjects_affected="48" subjects_at_risk="304"/>
                <counts group_id="E4" events="89" subjects_affected="56" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="34" subjects_affected="25" subjects_at_risk="315"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="297"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="304"/>
                <counts group_id="E4" events="21" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="315"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="304"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="212" subjects_affected="111" subjects_at_risk="315"/>
                <counts group_id="E2" events="178" subjects_affected="107" subjects_at_risk="297"/>
                <counts group_id="E3" events="249" subjects_affected="135" subjects_at_risk="304"/>
                <counts group_id="E4" events="187" subjects_affected="114" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="31" subjects_affected="20" subjects_at_risk="315"/>
                <counts group_id="E2" events="45" subjects_affected="31" subjects_at_risk="297"/>
                <counts group_id="E3" events="34" subjects_affected="22" subjects_at_risk="304"/>
                <counts group_id="E4" events="22" subjects_affected="20" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="315"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="297"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="304"/>
                <counts group_id="E4" events="19" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="315"/>
                <counts group_id="E2" events="43" subjects_affected="38" subjects_at_risk="297"/>
                <counts group_id="E3" events="58" subjects_affected="45" subjects_at_risk="304"/>
                <counts group_id="E4" events="51" subjects_affected="34" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="445" subjects_affected="192" subjects_at_risk="315"/>
                <counts group_id="E2" events="481" subjects_affected="200" subjects_at_risk="297"/>
                <counts group_id="E3" events="492" subjects_affected="195" subjects_at_risk="304"/>
                <counts group_id="E4" events="351" subjects_affected="177" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="59" subjects_affected="32" subjects_at_risk="315"/>
                <counts group_id="E2" events="51" subjects_affected="30" subjects_at_risk="297"/>
                <counts group_id="E3" events="34" subjects_affected="25" subjects_at_risk="304"/>
                <counts group_id="E4" events="53" subjects_affected="33" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="135" subjects_affected="73" subjects_at_risk="315"/>
                <counts group_id="E2" events="114" subjects_affected="72" subjects_at_risk="297"/>
                <counts group_id="E3" events="116" subjects_affected="74" subjects_at_risk="304"/>
                <counts group_id="E4" events="112" subjects_affected="66" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="51" subjects_at_risk="315"/>
                <counts group_id="E2" events="101" subjects_affected="74" subjects_at_risk="297"/>
                <counts group_id="E3" events="82" subjects_affected="58" subjects_at_risk="304"/>
                <counts group_id="E4" events="105" subjects_affected="64" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="92" subjects_affected="65" subjects_at_risk="315"/>
                <counts group_id="E2" events="76" subjects_affected="53" subjects_at_risk="297"/>
                <counts group_id="E3" events="84" subjects_affected="57" subjects_at_risk="304"/>
                <counts group_id="E4" events="106" subjects_affected="74" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="315"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="297"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="304"/>
                <counts group_id="E4" events="19" subjects_affected="17" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="315"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="297"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="304"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="315"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="297"/>
                <counts group_id="E3" events="36" subjects_affected="30" subjects_at_risk="304"/>
                <counts group_id="E4" events="18" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="315"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="304"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="315"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="304"/>
                <counts group_id="E4" events="22" subjects_affected="16" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="75" subjects_affected="64" subjects_at_risk="315"/>
                <counts group_id="E2" events="82" subjects_affected="68" subjects_at_risk="297"/>
                <counts group_id="E3" events="113" subjects_affected="104" subjects_at_risk="304"/>
                <counts group_id="E4" events="78" subjects_affected="67" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="315"/>
                <counts group_id="E2" events="38" subjects_affected="33" subjects_at_risk="297"/>
                <counts group_id="E3" events="33" subjects_affected="29" subjects_at_risk="304"/>
                <counts group_id="E4" events="30" subjects_affected="27" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="315"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="297"/>
                <counts group_id="E3" events="23" subjects_affected="17" subjects_at_risk="304"/>
                <counts group_id="E4" events="16" subjects_affected="13" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="38" subjects_affected="30" subjects_at_risk="315"/>
                <counts group_id="E2" events="45" subjects_affected="37" subjects_at_risk="297"/>
                <counts group_id="E3" events="30" subjects_affected="28" subjects_at_risk="304"/>
                <counts group_id="E4" events="28" subjects_affected="22" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E3" events="27" subjects_affected="24" subjects_at_risk="304"/>
                <counts group_id="E4" events="19" subjects_affected="18" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="315"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide the Sponsor thirty (30) days prior to submission for publication or presentation, copies of abstracts or manuscripts for publication which report project results. The Sponsor shall have editorial rights with respect to Publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to (a) proprietary information and, (b) the accuracy of the information contained in the Publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Adverse Event (AE) Preferred Terms were converted from WHO-ART dictionary to the MedDRA version 21.0</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

